U.S. FDA grants orphan drug status to AstraZeneca's asthma drug Fasenra

AstraZeneca said on Wednesday that the U.S. Food and Drug Administration has granted orphan drug status to its severe asthma drug, Fasenra, to treat eosinophilic oesophagitis (EoE).